Can Genomic Classifiers in Biopsy Cores With Grade Group 1 Cancer Predict Higher-Grade Disease Elsewhere in the Prostate? Results From the Prospective Miami Active Surveillance Trial

Genomic classifiers in GG1 cores did not predict coexisting GG2+ cancer, while dGPS signatures showed some promise in detecting GG3+ cancer elsewhere in the gland. None of the signatures showed a difference between groups when using the highest volume GG1 core, which is the standard practice for genomic classifiers.